首页 > 最新文献

The American journal of Chinese medicine最新文献

英文 中文
Multidirectional Intervention of Chinese Herbal Medicine in the Prevention and Treatment of Atherosclerosis: From Endothelial Protection to Immunomodulation. 中药在动脉粥样硬化防治中的多向干预:从内皮保护到免疫调节。
Pub Date : 2024-01-01 Epub Date: 2024-05-27 DOI: 10.1142/S0192415X24500381
Jia-Ni Li, Meng-Yu Wang, Yu-Rong Tan, Li-Li Wang

Atherosclerosis is a significant risk factor for developing cardiovascular disease and a leading cause of death worldwide. The occurrence of atherosclerosis is closely related to factors such as endothelial injury, lipid deposition, immunity, and inflammation. Conventional statins, currently used in atherosclerosis treatment, have numerous adverse side effects that limit their clinical utility, prompting the urgent need to identify safer and more effective therapeutic alternatives. Growing evidence indicates the significant potential of Chinese herbs in atherosclerosis treatment. Herbal monomer components, such as natural flavonoid compounds extracted from herbs like Coptis chinensis and Panax notoginseng, have been utilized for their lipid-lowering and inflammation-inhibiting effects in atherosclerosis treatment. These herbs can be used as single components in treating diseases and with other Chinese medicines to form herbal combinations. This approach targets the disease mechanism in multiple ways, enhancing the therapeutic effects. Thus, this review examines the roles of Chinese herbal medicine monomers and Chinese herbal compounds in inhibiting atherosclerosis, including regulating lipids, improving endothelial function, reducing oxidative stress, regulating inflammation and the immune response, and apoptosis. By highlighting these roles, our study offers new perspectives on atherosclerosis treatment with Chinese herbs and is anticipated to contribute to advancements in related research fields.

动脉粥样硬化是罹患心血管疾病的重要风险因素,也是导致全球死亡的主要原因。动脉粥样硬化的发生与内皮损伤、脂质沉积、免疫和炎症等因素密切相关。目前用于治疗动脉粥样硬化的传统他汀类药物有许多不良副作用,限制了其临床应用,因此迫切需要找到更安全、更有效的替代治疗药物。越来越多的证据表明,中草药在治疗动脉粥样硬化方面具有巨大潜力。中草药单体成分,如从黄连和三七等中草药中提取的天然类黄酮化合物,具有降血脂和抑制炎症的作用,已被用于动脉粥样硬化的治疗。这些中草药既可作为单一成分用于治疗疾病,也可与其他中药组成中草药组合。这种方法以多种方式针对疾病机制,增强了治疗效果。因此,本综述探讨了中药单体和中药复方在抑制动脉粥样硬化方面的作用,包括调节血脂、改善内皮功能、减少氧化应激、调节炎症和免疫反应以及细胞凋亡。通过强调这些作用,我们的研究为用中草药治疗动脉粥样硬化提供了新的视角,并有望推动相关研究领域的进展。
{"title":"Multidirectional Intervention of Chinese Herbal Medicine in the Prevention and Treatment of Atherosclerosis: From Endothelial Protection to Immunomodulation.","authors":"Jia-Ni Li, Meng-Yu Wang, Yu-Rong Tan, Li-Li Wang","doi":"10.1142/S0192415X24500381","DOIUrl":"10.1142/S0192415X24500381","url":null,"abstract":"<p><p>Atherosclerosis is a significant risk factor for developing cardiovascular disease and a leading cause of death worldwide. The occurrence of atherosclerosis is closely related to factors such as endothelial injury, lipid deposition, immunity, and inflammation. Conventional statins, currently used in atherosclerosis treatment, have numerous adverse side effects that limit their clinical utility, prompting the urgent need to identify safer and more effective therapeutic alternatives. Growing evidence indicates the significant potential of Chinese herbs in atherosclerosis treatment. Herbal monomer components, such as natural flavonoid compounds extracted from herbs like <i>Coptis chinensis</i> and <i>Panax notoginseng</i>, have been utilized for their lipid-lowering and inflammation-inhibiting effects in atherosclerosis treatment. These herbs can be used as single components in treating diseases and with other Chinese medicines to form herbal combinations. This approach targets the disease mechanism in multiple ways, enhancing the therapeutic effects. Thus, this review examines the roles of Chinese herbal medicine monomers and Chinese herbal compounds in inhibiting atherosclerosis, including regulating lipids, improving endothelial function, reducing oxidative stress, regulating inflammation and the immune response, and apoptosis. By highlighting these roles, our study offers new perspectives on atherosclerosis treatment with Chinese herbs and is anticipated to contribute to advancements in related research fields.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"925-947"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141156034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Inflammatory Effects of Lupeol as a Candidate for New Drug Development. 作为新药开发候选药物的羽扇豆醇的抗炎作用
Pub Date : 2024-01-01 Epub Date: 2024-09-26 DOI: 10.1142/S0192415X2450068X
Yun Jin Park, Dong Ho Park, Jong-Sup Bae

This study explores the anti-inflammatory properties of lupeol, a notable phytosterol found in various medicinal plants, highlighting its potential as a candidate for new drug development. We examined the effects of lupeol on heme oxygenase (HO)-1, cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs), as well as its impact on inflammatory markers in the lung tissues of LPS-challenged mice. Lupeol treatment enhanced HO-1 production, inhibited nuclear factor (NF)-κB activity, and reduced levels of COX-2/prostaglandin E2 (PGE2) and iNOS/nitric oxide (NO). In addition, lupeol decreased the phosphorylation of signal transducer and activator of transcription 1 (STAT-1) and promoted the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), enhancing its binding to the anti-oxidant response element (ARE) and subsequently reducing interleukin (IL)-1β expression. In vivo, lupeol significantly lowered iNOS expression and tumor necrosis factor (TNF)-α levels in bronchoalveolar lavage fluid from LPS-treated mice. These findings suggest that lupeol exerts its anti-inflammatory effects by modulating key signaling pathways, positioning it as a promising candidate for the development of novel therapeutics targeting pathological inflammation.

羽扇豆醇是一种存在于多种药用植物中的著名植物甾醇,本研究探讨了羽扇豆醇的抗炎特性,强调了其作为新药开发候选物的潜力。我们研究了羽扇豆醇对脂多糖(LPS)刺激的人脐静脉内皮细胞(HUVECs)中血红素加氧酶(HO)-1、环氧化酶(COX)-2和诱导型一氧化氮合酶(iNOS)的影响,以及它对LPS挑战小鼠肺组织中炎症标志物的影响。羽扇豆醇能促进 HO-1 的产生,抑制核因子(NF)-κB 的活性,并降低 COX-2/前列腺素 E2(PGE2)和 iNOS/一氧化氮(NO)的水平。此外,羽扇豆醇还能减少信号转导和转录激活因子 1(STAT-1)的磷酸化,促进核因子红细胞 2 相关因子 2(Nrf2)的核转位,增强其与抗氧化反应元件(ARE)的结合,从而减少白细胞介素(IL)-1β的表达。在体内,羽扇豆醇能显著降低经 LPS 处理的小鼠支气管肺泡灌洗液中 iNOS 的表达和肿瘤坏死因子(TNF)-α 的水平。这些研究结果表明,羽扇豆醇通过调节关键信号通路来发挥抗炎作用,使其成为开发针对病理炎症的新型疗法的理想候选物质。
{"title":"Anti-Inflammatory Effects of Lupeol as a Candidate for New Drug Development.","authors":"Yun Jin Park, Dong Ho Park, Jong-Sup Bae","doi":"10.1142/S0192415X2450068X","DOIUrl":"10.1142/S0192415X2450068X","url":null,"abstract":"<p><p>This study explores the anti-inflammatory properties of lupeol, a notable phytosterol found in various medicinal plants, highlighting its potential as a candidate for new drug development. We examined the effects of lupeol on heme oxygenase (HO)-1, cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs), as well as its impact on inflammatory markers in the lung tissues of LPS-challenged mice. Lupeol treatment enhanced HO-1 production, inhibited nuclear factor (NF)-κB activity, and reduced levels of COX-2/prostaglandin E2 (PGE2) and iNOS/nitric oxide (NO). In addition, lupeol decreased the phosphorylation of signal transducer and activator of transcription 1 (STAT-1) and promoted the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), enhancing its binding to the anti-oxidant response element (ARE) and subsequently reducing interleukin (IL)-1β expression. <i>In vivo</i>, lupeol significantly lowered iNOS expression and tumor necrosis factor (TNF)-α levels in bronchoalveolar lavage fluid from LPS-treated mice. These findings suggest that lupeol exerts its anti-inflammatory effects by modulating key signaling pathways, positioning it as a promising candidate for the development of novel therapeutics targeting pathological inflammation.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1759-1771"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Progress of Chinese Medicine in the Regulation of Liver Fibrosis-Related Signaling Pathways. 中医药调控肝纤维化相关信号通路的研究进展。
Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1142/S0192415X24500666
Shihao Zheng, Chengyuan Xue, Size Li, Wenying Qi, Xiaobin Zao, Xiaoke Li, Wei Wang, Qiyao Liu, Xu Cao, Peng Zhang, Yongan Ye

Liver fibrosis is a common complication of chronic liver disease, significantly affecting patients' quality of life and potentially leading to cirrhosis and hepatocellular carcinoma. Despite advancements in modern medicine, the treatment of liver fibrosis remains limited and challenging. Thus, identifying new therapeutic strategies is of great clinical importance. Signaling pathways related to liver fibrosis play a crucial regulatory role in immune response and inflammation. Aberrant activation of specific pathways, such as the NF-κB signaling pathway, results in the overexpression of genes associated with liver inflammation and fibrosis, thereby promoting the progression of liver fibrosis. Chinese medicine offers unique potential advantages as a therapeutic approach. Recent studies have increasingly demonstrated that certain Chinese medicines can effectively treat liver fibrosis by regulating relevant signaling pathways. The active ingredients in these medicines can inhibit hepatic inflammatory responses and fibrotic processes by interfering with these pathways, thus reducing the severity of liver fibrosis. This paper aims to investigate the mechanisms of Chinese medicine in treating liver fibrosis and its modulation of related signaling pathways. Additionally, it discusses the prospects of the clinical application of these treatments and provides valuable references for further research and clinical practice.

肝纤维化是慢性肝病的常见并发症,严重影响患者的生活质量,并可能导致肝硬化和肝细胞癌。尽管现代医学不断进步,但肝纤维化的治疗方法仍然有限,且具有挑战性。因此,确定新的治疗策略具有重要的临床意义。与肝纤维化相关的信号通路在免疫反应和炎症中发挥着重要的调节作用。特定通路的异常激活,如NF-[配方: 见正文]B信号通路,会导致与肝脏炎症和纤维化相关的基因过度表达,从而促进肝纤维化的进展。中医药作为一种治疗方法具有独特的潜在优势。最近的研究越来越多地表明,某些中药可通过调节相关信号通路有效治疗肝纤维化。这些中药的有效成分可以通过干扰这些通路来抑制肝脏炎症反应和纤维化过程,从而减轻肝纤维化的严重程度。本文旨在研究中药治疗肝纤维化的机制及其对相关信号通路的调节作用。此外,本文还探讨了这些疗法的临床应用前景,并为进一步的研究和临床实践提供了有价值的参考。
{"title":"Research Progress of Chinese Medicine in the Regulation of Liver Fibrosis-Related Signaling Pathways.","authors":"Shihao Zheng, Chengyuan Xue, Size Li, Wenying Qi, Xiaobin Zao, Xiaoke Li, Wei Wang, Qiyao Liu, Xu Cao, Peng Zhang, Yongan Ye","doi":"10.1142/S0192415X24500666","DOIUrl":"10.1142/S0192415X24500666","url":null,"abstract":"<p><p>Liver fibrosis is a common complication of chronic liver disease, significantly affecting patients' quality of life and potentially leading to cirrhosis and hepatocellular carcinoma. Despite advancements in modern medicine, the treatment of liver fibrosis remains limited and challenging. Thus, identifying new therapeutic strategies is of great clinical importance. Signaling pathways related to liver fibrosis play a crucial regulatory role in immune response and inflammation. Aberrant activation of specific pathways, such as the NF-κB signaling pathway, results in the overexpression of genes associated with liver inflammation and fibrosis, thereby promoting the progression of liver fibrosis. Chinese medicine offers unique potential advantages as a therapeutic approach. Recent studies have increasingly demonstrated that certain Chinese medicines can effectively treat liver fibrosis by regulating relevant signaling pathways. The active ingredients in these medicines can inhibit hepatic inflammatory responses and fibrotic processes by interfering with these pathways, thus reducing the severity of liver fibrosis. This paper aims to investigate the mechanisms of Chinese medicine in treating liver fibrosis and its modulation of related signaling pathways. Additionally, it discusses the prospects of the clinical application of these treatments and provides valuable references for further research and clinical practice.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1693-1728"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fucoxanthin Prevents Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Ferroptosis via Nrf2/STAT3 and Glutathione Pathways. 岩藻黄素通过 Nrf2/STAT3 和谷胱甘肽途径抑制铁卟啉沉积,从而预防脂多糖诱发的急性肺损伤
Pub Date : 2024-01-01 Epub Date: 2024-11-21 DOI: 10.1142/S0192415X24500691
Rui Ding, Sai-Yi Zhong, Li-Yan Deng, Lian-Xiang Luo

Fucoxanthin, sourced from marine brown algae, diatoms, and microalgae, is known to possess strong anti-inflammatory activity. To explore its intrinsic mechanism, we investigated its effects on acute lung injury (ALI) with an experiment using lipopolysaccharide (LPS)-induced RAW264.7 inflammatory cells and an ALI animal model. Fucoxanthin was observed to suppress the inflammatory response in vitro by reducing the levels of inflammatory markers such as PTGS2, iNOS, and TNF-α. Network pharmacology analysis revealed that fucoxanthin could potentially inhibit ferroptosis through 10 targets, including PTGS2. This was further confirmed by the dose-dependent increase in lipid peroxidation and Fe[Formula: see text] levels caused by fucoxanthin, as well as the regulation of ferroptosis-associated proteins ACSL4, SLC7A11, GPX4, and FTH1. Furthermore, fucoxanthin was found to significantly reduce the inflammatory response and ferroptosis in a mouse model of LPS-induced ALI. Further research revealed that fucoxanthin could raise the levels of [Formula: see text]-Glu-Cys and carbamyl glycine, which are intermediate metabolites of glutathione synthesis, in RAW264.7 cells. This implies that fucoxanthin can inhibit ferroptosis by regulating the [Formula: see text]-glutamyl cycle. Our research demonstrated that fucoxanthin is capable of activating phosphorylated STAT3 and raising the expression of Nrf2 and HO-1, implying that fucoxanthin may be able to prevent LPS-induced ferroptosis in ALI through the Nrf2/STAT3 pathway.

众所周知,从海洋褐藻、硅藻和微藻中提取的岩藻黄素具有很强的抗炎活性。为了探索其内在机制,我们使用脂多糖(LPS)诱导的 RAW264.7 炎症细胞和 ALI 动物模型进行实验,研究其对急性肺损伤(ALI)的影响。通过降低炎症标志物(如 PTGS2、iNOS 和 TNF-α)的水平,观察到岩藻黄质可抑制体外炎症反应。网络药理学分析表明,岩藻黄素可通过包括 PTGS2 在内的 10 个靶点抑制铁变态反应。这一点还得到了进一步的证实,因为葫芦黄素会导致脂质过氧化和铁[式:见正文]含量的剂量依赖性增加,并调节铁变态相关蛋白ACSL4、SLC7A11、GPX4和FTH1。此外,研究还发现,在 LPS 诱导的 ALI 小鼠模型中,葫芦黄素能显著降低炎症反应和铁变态反应。进一步的研究发现,在RAW264.7细胞中,狐黄素可以提高谷胱甘肽合成的中间代谢产物[配方:见正文]-Glu-Cys和氨甲酰甘氨酸的水平。这意味着,狐黄素可以通过调节[式:见正文]-谷氨酰循环来抑制铁变态反应。我们的研究表明,葫芦黄素能够激活磷酸化的STAT3,并提高Nrf2和HO-1的表达,这意味着葫芦黄素可能能够通过Nrf2/STAT3途径防止LPS诱导的ALI铁变态反应。
{"title":"Fucoxanthin Prevents Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Ferroptosis via Nrf2/STAT3 and Glutathione Pathways.","authors":"Rui Ding, Sai-Yi Zhong, Li-Yan Deng, Lian-Xiang Luo","doi":"10.1142/S0192415X24500691","DOIUrl":"10.1142/S0192415X24500691","url":null,"abstract":"<p><p>Fucoxanthin, sourced from marine brown algae, diatoms, and microalgae, is known to possess strong anti-inflammatory activity. To explore its intrinsic mechanism, we investigated its effects on acute lung injury (ALI) with an experiment using lipopolysaccharide (LPS)-induced RAW264.7 inflammatory cells and an ALI animal model. Fucoxanthin was observed to suppress the inflammatory response <i>in vitro</i> by reducing the levels of inflammatory markers such as PTGS2, iNOS, and TNF-α. Network pharmacology analysis revealed that fucoxanthin could potentially inhibit ferroptosis through 10 targets, including PTGS2. This was further confirmed by the dose-dependent increase in lipid peroxidation and Fe[Formula: see text] levels caused by fucoxanthin, as well as the regulation of ferroptosis-associated proteins ACSL4, SLC7A11, GPX4, and FTH1. Furthermore, fucoxanthin was found to significantly reduce the inflammatory response and ferroptosis in a mouse model of LPS-induced ALI. Further research revealed that fucoxanthin could raise the levels of [Formula: see text]-Glu-Cys and carbamyl glycine, which are intermediate metabolites of glutathione synthesis, in RAW264.7 cells. This implies that fucoxanthin can inhibit ferroptosis by regulating the [Formula: see text]-glutamyl cycle. Our research demonstrated that fucoxanthin is capable of activating phosphorylated STAT3 and raising the expression of Nrf2 and HO-1, implying that fucoxanthin may be able to prevent LPS-induced ferroptosis in ALI through the Nrf2/STAT3 pathway.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1773-1794"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends and Characteristics of the Whole-Grain Diet. 全谷物饮食的趋势和特点。
Pub Date : 2024-01-01 Epub Date: 2024-11-27 DOI: 10.1142/S0192415X24500769
Qingyan Pei, Chuan Chen, Hao Bai, Yirong Xi, Leilei Zhang, Haiming Li, Houfu Liu, Yibin Hao

Whole-grain foods are good choices for a nutritious diet and play an important role in lowering the risk of chronic diseases. China is a large cereal-consuming country that is experiencing rapid economic growth and an increased burden of noncommunicable diseases. Studies have shown that insufficient intake of whole grains has increased the burden on public health to some extent. Therefore, we aimed to analyze the characteristics and trends of whole-grain consumption in China to contribute to the development of a healthy Chinese population. We searched for important policies, standards, and dietary recommendations related to whole grains through the official websites of the China State Council and its affiliated ministries. Official and public databases, such as the National Bureau of Statistics and the China Health and Nutrition Survey (CHNS), were utilized to obtain data on whole grains and different foods. This approach was employed to gain insight into changes in whole-grain intake levels and dietary structure. Since 2010, the development of whole grains in China has received significant attention. Supportive policies have been continuously introduced on both the supply and demand sides. Numerous whole-grain standards have been developed, and terms and definitions related to whole grains have been preliminarily defined. The consumption of whole grains has fluctuated among Chinese residents since 2000, with a downward trend from 2000 to 2009, followed by an upward trend from 2009 to 2018. However, despite this increasing trend, the whole-grain intake of 80% of the adult residents was still lower than the minimum recommended dietary intake (50[Formula: see text]g/day). Furthermore, the dietary structure of Chinese residents has undergone a significant transformation, characterized by high consumption of high-fat foods, excessive consumption of meat, low intake of dietary fiber, and insufficient consumption of whole grains. These findings highlight the need for further monitoring of whole-grain intake in China. In addition, a sound whole-grain standardization system should be established, and the availability and consumer awareness of whole grains should be improved, with the goal of increasing the intake of whole grains.

全谷物食品是营养膳食的良好选择,在降低慢性疾病风险方面发挥着重要作用。中国是谷物消费大国,经济增长迅速,非传染性疾病负担加重。研究表明,全谷物摄入不足在一定程度上增加了公众的健康负担。因此,我们旨在分析中国全谷物消费的特点和趋势,为中国人口的健康发展做出贡献。我们通过中国国务院及其所属部委的官方网站搜索了与全谷物相关的重要政策、标准和膳食建议。我们还利用官方和公共数据库,如国家统计局和中国健康与营养调查(CHNS),获取有关全谷物和不同食品的数据。通过这种方法可以深入了解全谷物摄入水平和膳食结构的变化。自 2010 年以来,全谷物食品在中国的发展备受关注。供需双方不断出台扶持政策。制定了众多全谷物标准,初步确定了全谷物相关术语和定义。自 2000 年以来,中国居民的全谷物消费量有所波动,2000 年至 2009 年呈下降趋势,2009 年至 2018 年呈上升趋势。然而,尽管呈上升趋势,80%的成年居民的全谷物摄入量仍低于最低推荐膳食摄入量(50[计算公式:见正文]克/天)。此外,中国居民的膳食结构也发生了显著变化,表现为高脂肪食物摄入量高、肉类摄入量过多、膳食纤维摄入量低以及全谷物摄入量不足。这些发现凸显了进一步监测中国居民全谷物摄入量的必要性。此外,还应建立健全全谷物标准化体系,提高全谷物的可获得性和消费者对全谷物的认知度,从而达到增加全谷物摄入量的目的。
{"title":"Trends and Characteristics of the Whole-Grain Diet.","authors":"Qingyan Pei, Chuan Chen, Hao Bai, Yirong Xi, Leilei Zhang, Haiming Li, Houfu Liu, Yibin Hao","doi":"10.1142/S0192415X24500769","DOIUrl":"10.1142/S0192415X24500769","url":null,"abstract":"<p><p>Whole-grain foods are good choices for a nutritious diet and play an important role in lowering the risk of chronic diseases. China is a large cereal-consuming country that is experiencing rapid economic growth and an increased burden of noncommunicable diseases. Studies have shown that insufficient intake of whole grains has increased the burden on public health to some extent. Therefore, we aimed to analyze the characteristics and trends of whole-grain consumption in China to contribute to the development of a healthy Chinese population. We searched for important policies, standards, and dietary recommendations related to whole grains through the official websites of the China State Council and its affiliated ministries. Official and public databases, such as the National Bureau of Statistics and the China Health and Nutrition Survey (CHNS), were utilized to obtain data on whole grains and different foods. This approach was employed to gain insight into changes in whole-grain intake levels and dietary structure. Since 2010, the development of whole grains in China has received significant attention. Supportive policies have been continuously introduced on both the supply and demand sides. Numerous whole-grain standards have been developed, and terms and definitions related to whole grains have been preliminarily defined. The consumption of whole grains has fluctuated among Chinese residents since 2000, with a downward trend from 2000 to 2009, followed by an upward trend from 2009 to 2018. However, despite this increasing trend, the whole-grain intake of 80% of the adult residents was still lower than the minimum recommended dietary intake (50[Formula: see text]g/day). Furthermore, the dietary structure of Chinese residents has undergone a significant transformation, characterized by high consumption of high-fat foods, excessive consumption of meat, low intake of dietary fiber, and insufficient consumption of whole grains. These findings highlight the need for further monitoring of whole-grain intake in China. In addition, a sound whole-grain standardization system should be established, and the availability and consumer awareness of whole grains should be improved, with the goal of increasing the intake of whole grains.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1969-1987"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Catalpol from Rehmannia glutinosa Targets Nrf2/NF-κB Signaling Pathway to Improve Renal Anemia and Fibrosis. 地黄中的梓醇靶向 Nrf2/NF-[式中:见正文]B 信号通路,改善肾脏贫血和纤维化。
Pub Date : 2024-01-01 Epub Date: 2024-07-30 DOI: 10.1142/S0192415X24500575
Zhi-Hui Liu, Qing-Yang Xu, Yu Wang, Hong-Xin Gao, Ya-Hong Min, Xiao-Wen Jiang, Wen-Hui Yu

Rehmannia glutinosa is widely recognized as a prominent medicinal herb employed by practitioners across various generations for the purpose of fortifying kidney yin. Within Rehmannia glutinosa, the compound known as catalpol (CAT) holds significant importance as a bioactive constituent. However, the protective effects of CAT on kidneys, including ameliorative effects on chronic kidney disease - most prominently renal anemia and renal fibrosis - have not been clearly defined. In this study, the kidney injury model of NRK-52E cells and C57BL/6N male mice was prepared by exposure to aristolochic acid I (AA-I), and it was discovered that CAT could ameliorate oxidative stress injury, inflammatory injury, apoptosis, renal anemia, renal fibrosis, and other renal injuries both in vivo and in vitro. Further treatment of NRK-52E cells with Nrf2 inhibitors (ML385) and activators (ML334), as well as NF-κB inhibitors (PDTC), validated CAT's ability to target Nrf2 activation. Furthermore, the expression of phosphorylated NF-κB p65, IL-6, and Cleaved-Caspase3 protein was inhibited. CAT also inhibited NF-κB, and then inhibited the expression of IL-6, p-STAS3, TGF-β1 protein. Therefore, CAT can regulate Nrf2/NF-κB signaling pathway, significantly correct renal anemia and renal fibrosis, and is conducive to the preservation of renal structure and function, thus achieving a protective effect on the kidneys.

地黄被公认为是一种著名的药材,历代医家都将其用于滋补肾阴。在地黄中,被称为梓醇(CAT)的化合物作为一种生物活性成分具有重要意义。然而,CAT 对肾脏的保护作用,包括对慢性肾脏疾病(最突出的是肾性贫血和肾脏纤维化)的改善作用,尚未得到明确界定。本研究通过马兜铃酸 I(AA-I)暴露制备了 NRK-52E 细胞和 C57BL/6N 雄性小鼠肾损伤模型,发现 CAT 在体内和体外均能改善氧化应激损伤、炎症损伤、细胞凋亡、肾性贫血、肾纤维化和其他肾损伤。用 Nrf2 抑制剂(ML385)和激活剂(ML334)以及 NF-[式中:见正文]B 抑制剂(PDTC)进一步处理 NRK-52E 细胞,验证了 CAT 靶向激活 Nrf2 的能力。此外,磷酸化 NF-[式中:见正文]B p65、IL-6 和裂解-Caspase3 蛋白的表达也受到了抑制。CAT 还能抑制 NF-[式:见正文]B,进而抑制 IL-6、p-STAS3 和 TGF-[式:见正文]1 蛋白的表达。因此,CAT能调节Nrf2/NF-[式:见正文]B信号通路,显著纠正肾性贫血和肾纤维化,有利于保护肾脏结构和功能,从而达到保护肾脏的作用。
{"title":"Catalpol from <i>Rehmannia glutinosa</i> Targets Nrf2/NF-κB Signaling Pathway to Improve Renal Anemia and Fibrosis.","authors":"Zhi-Hui Liu, Qing-Yang Xu, Yu Wang, Hong-Xin Gao, Ya-Hong Min, Xiao-Wen Jiang, Wen-Hui Yu","doi":"10.1142/S0192415X24500575","DOIUrl":"10.1142/S0192415X24500575","url":null,"abstract":"<p><p><i>Rehmannia glutinosa</i> is widely recognized as a prominent medicinal herb employed by practitioners across various generations for the purpose of fortifying kidney yin. Within <i>Rehmannia glutinosa</i>, the compound known as catalpol (CAT) holds significant importance as a bioactive constituent. However, the protective effects of CAT on kidneys, including ameliorative effects on chronic kidney disease - most prominently renal anemia and renal fibrosis - have not been clearly defined. In this study, the kidney injury model of NRK-52E cells and C57BL/6N male mice was prepared by exposure to aristolochic acid I (AA-I), and it was discovered that CAT could ameliorate oxidative stress injury, inflammatory injury, apoptosis, renal anemia, renal fibrosis, and other renal injuries both <i>in vivo</i> and <i>in vitro</i>. Further treatment of NRK-52E cells with Nrf2 inhibitors (ML385) and activators (ML334), as well as NF-κB inhibitors (PDTC), validated CAT's ability to target Nrf2 activation. Furthermore, the expression of phosphorylated NF-κB p65, IL-6, and Cleaved-Caspase3 protein was inhibited. CAT also inhibited NF-κB, and then inhibited the expression of IL-6, p-STAS3, TGF-β1 protein. Therefore, CAT can regulate Nrf2/NF-κB signaling pathway, significantly correct renal anemia and renal fibrosis, and is conducive to the preservation of renal structure and function, thus achieving a protective effect on the kidneys.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1451-1485"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Exploration of the Neuroprotective Mechanisms of Ginkgo biloba Leaves in Treating Neurological Disorders. 全面探索银杏叶治疗神经系统疾病的神经保护机制。
Pub Date : 2024-01-01 Epub Date: 2024-06-21 DOI: 10.1142/S0192415X24500435
Qiwei Liu, Jinghui Wang, Zongyun Gu, Ting Ouyang, Honglei Gao, Hongxing Kan, Yinfeng Yang

Neurological disorders (NDs) are diseases that seriously affect the health of individuals worldwide, potentially leading to a significant reduction in the quality of life for patients and their families. Herbal medicines have been widely used in the treatment of NDs due to their multi-target and multi-pathway features. Ginkgo biloba leaves (GBLs), one of the most popular herbal medicines in the world, have been demonstrated to present therapeutic effects on NDs. However, the pharmacological mechanisms of GBLs in the treatment of neurological disorders have not been systematically summarized. This study aimed to summarize the molecular mechanism of GBLs in treating NDs from the cell models, animal models, and clinical trials of studies. Four databases, i.e., PubMed, Google Scholar, CNKI, and Web of Science were searched using the following keywords: "Ginkgo biloba", "Ginkgo biloba extract", "Ginkgo biloba leaves", "Ginkgo biloba leaves extract", "Neurological disorders", "Neurological diseases", and "Neurodegenerative diseases". All items meeting the inclusion criteria on the treatment of NDs with GBLs were extracted and summarized. Additionally, PRISMA 2020 was performed to independently evaluate the screening methods. Out of 1385 records in the database, 52 were screened in relation to the function of GBLs in the treatment of NDs; of these 52 records, 39 were preclinical trials and 13 were clinical studies. Analysis of pharmacological studies revealed that GBLs can improve memory, cognition, behavior, and psychopathology of NDs and that the most frequently associated GBLs are depression, followed by Alzheimer's disease, stroke, Huntington's disease, and Parkinson's disease. Additionally, the clinical studies of depression, AD, and stroke are the most common, and most of the remaining ND data are available from in vitro or in vivo animal studies. Moreover, the possible mechanisms of GBLs in treating NDs are mainly through free radical scavenging, anti-oxidant activity, anti-inflammatory response, mitochondrial protection, neurotransmitter regulation, and antagonism of PAF. This is the first paper to systematically and comprehensively investigate the pharmacological effects and neuroprotective mechanisms of GBLs in the treatment of NDs thus far. All findings contribute to a better understanding of the efficacy and complexity of GBLs in treating NDs, which is of great significance for the further clinical application of this herbal medicine.

神经系统疾病(NDs)是严重影响全球个人健康的疾病,可能导致患者及其家人的生活质量显著下降。由于中草药具有多靶点、多途径的特点,因此被广泛用于治疗 NDs。银杏叶(GBLs)是世界上最受欢迎的草药之一,已被证实对 NDs 具有治疗作用。然而,GBLs 治疗神经系统疾病的药理机制尚未得到系统总结。本研究旨在从细胞模型、动物模型和临床试验研究中总结GBLs治疗NDs的分子机制。本研究使用以下关键词检索了四个数据库,即 PubMed、Google Scholar、CNKI 和 Web of Science:"银杏叶"、"银杏叶提取物"、"银杏叶"、"银杏叶提取物"、"神经系统疾病"、"神经系统疾病 "和 "神经退行性疾病"。提取并汇总了所有符合纳入标准的有关用 GBL 治疗 NDs 的项目。此外,还对筛选方法进行了PRISMA 2020独立评估。在数据库的 1385 条记录中,筛选出 52 条与 GBLs 治疗 NDs 功能相关的记录;在这 52 条记录中,39 条为临床前试验,13 条为临床研究。药理学研究分析表明,GBLs可以改善NDs的记忆、认知、行为和精神病理学,最常见的相关GBLs是抑郁症,其次是阿尔茨海默病、中风、亨廷顿病和帕金森病。此外,抑郁症、阿尔兹海默病和中风的临床研究最为常见,其余的玖玖彩票网正规吗数据大多来自体外或体内动物研究。此外,GBLs治疗NDs的可能机制主要是通过清除自由基、抗氧化活性、抗炎反应、线粒体保护、神经递质调节和拮抗PAF。这是迄今为止第一篇系统、全面地研究 GBLs 治疗 NDs 的药理作用和神经保护机制的论文。所有研究结果都有助于更好地理解GBLs治疗NDs的疗效和复杂性,这对该中药的进一步临床应用具有重要意义。
{"title":"Comprehensive Exploration of the Neuroprotective Mechanisms of <i>Ginkgo biloba</i> Leaves in Treating Neurological Disorders.","authors":"Qiwei Liu, Jinghui Wang, Zongyun Gu, Ting Ouyang, Honglei Gao, Hongxing Kan, Yinfeng Yang","doi":"10.1142/S0192415X24500435","DOIUrl":"10.1142/S0192415X24500435","url":null,"abstract":"<p><p>Neurological disorders (NDs) are diseases that seriously affect the health of individuals worldwide, potentially leading to a significant reduction in the quality of life for patients and their families. Herbal medicines have been widely used in the treatment of NDs due to their multi-target and multi-pathway features. <i>Ginkgo biloba</i> leaves (<i>GB</i>Ls), one of the most popular herbal medicines in the world, have been demonstrated to present therapeutic effects on NDs. However, the pharmacological mechanisms of <i>GB</i>Ls in the treatment of neurological disorders have not been systematically summarized. This study aimed to summarize the molecular mechanism of <i>GB</i>Ls in treating NDs from the cell models, animal models, and clinical trials of studies. Four databases, i.e., PubMed, Google Scholar, CNKI, and Web of Science were searched using the following keywords: \"<i>Ginkgo biloba</i>\", \"<i>Ginkgo biloba</i> extract\", \"<i>Ginkgo biloba</i> leaves\", \"<i>Ginkgo biloba</i> leaves extract\", \"Neurological disorders\", \"Neurological diseases\", and \"Neurodegenerative diseases\". All items meeting the inclusion criteria on the treatment of NDs with <i>GB</i>Ls were extracted and summarized. Additionally, PRISMA 2020 was performed to independently evaluate the screening methods. Out of 1385 records in the database, 52 were screened in relation to the function of <i>GB</i>Ls in the treatment of NDs; of these 52 records, 39 were preclinical trials and 13 were clinical studies. Analysis of pharmacological studies revealed that <i>GB</i>Ls can improve memory, cognition, behavior, and psychopathology of NDs and that the most frequently associated <i>GB</i>Ls are depression, followed by Alzheimer's disease, stroke, Huntington's disease, and Parkinson's disease. Additionally, the clinical studies of depression, AD, and stroke are the most common, and most of the remaining ND data are available from <i>in vitro</i> or <i>in vivo</i> animal studies. Moreover, the possible mechanisms of <i>GB</i>Ls in treating NDs are mainly through free radical scavenging, anti-oxidant activity, anti-inflammatory response, mitochondrial protection, neurotransmitter regulation, and antagonism of PAF. This is the first paper to systematically and comprehensively investigate the pharmacological effects and neuroprotective mechanisms of <i>GB</i>Ls in the treatment of NDs thus far. All findings contribute to a better understanding of the efficacy and complexity of <i>GB</i>Ls in treating NDs, which is of great significance for the further clinical application of this herbal medicine.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1053-1086"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Mechanisms of Natural Products as Therapeutic Interventions for Chronic Respiratory Diseases. 天然产品作为慢性呼吸道疾病治疗干预措施的功效和机制。
Pub Date : 2024-01-01 Epub Date: 2024-02-14 DOI: 10.1142/S0192415X24500034
Fanli Jin, Pengbei Fan, Yuanyuan Wu, Qingzhen Yang, Jiansheng Li, Han Liu

Chronic respiratory diseases are long-term conditions affecting the airways and other lung components that are characterized by a high prevalence, disability rate, and mortality rate. Further optimization of their treatment is required. Natural products, primarily extracted from organisms, possess specific molecular and structural formulas as well as distinct chemical and physical properties. These characteristics grant them the advantages of safety, gentleness, accessibility, and minimal side effects. The numerous advances in the use of natural products for treating chronic respiratory diseases have provided a steady source of motivation for new drug research and development. In this paper, we introduced the pathogenesis of chronic respiratory diseases and natural products. Furthermore, we classified natural products according to their mechanism for treating chronic respiratory diseases and describe the ways in which these products can alleviate the pathological symptoms. Simultaneously, we elaborate on the signal transduction pathways and biological impacts of natural products' targeting. Additionally, we present future prospects for natural products, considering their combination treatment approaches and administration methods. The significance of this review extends to both the research on preventing and treating chronic respiratory diseases, as well as the advancement of novel drug development in this field.

慢性呼吸系统疾病是一种影响气道和其他肺部成分的长期疾病,具有发病率高、致残率高和死亡率高的特点。需要进一步优化其治疗方法。天然产品主要从生物体中提取,具有特定的分子和结构式,以及独特的化学和物理特性。这些特性使其具有安全、温和、易得、副作用小等优点。天然产物在治疗慢性呼吸系统疾病方面取得的诸多进展为新药研发提供了源源不断的动力。本文介绍了慢性呼吸系统疾病的发病机理和天然产物。此外,我们还根据天然产物治疗慢性呼吸系统疾病的机理对其进行了分类,并介绍了这些天然产物缓解病理症状的方法。同时,我们还阐述了天然产物靶向的信号转导途径和生物学影响。此外,考虑到天然产品的综合治疗方法和给药方式,我们还介绍了天然产品的未来前景。本综述对预防和治疗慢性呼吸系统疾病的研究以及该领域新药开发的进展都具有重要意义。
{"title":"Efficacy and Mechanisms of Natural Products as Therapeutic Interventions for Chronic Respiratory Diseases.","authors":"Fanli Jin, Pengbei Fan, Yuanyuan Wu, Qingzhen Yang, Jiansheng Li, Han Liu","doi":"10.1142/S0192415X24500034","DOIUrl":"10.1142/S0192415X24500034","url":null,"abstract":"<p><p>Chronic respiratory diseases are long-term conditions affecting the airways and other lung components that are characterized by a high prevalence, disability rate, and mortality rate. Further optimization of their treatment is required. Natural products, primarily extracted from organisms, possess specific molecular and structural formulas as well as distinct chemical and physical properties. These characteristics grant them the advantages of safety, gentleness, accessibility, and minimal side effects. The numerous advances in the use of natural products for treating chronic respiratory diseases have provided a steady source of motivation for new drug research and development. In this paper, we introduced the pathogenesis of chronic respiratory diseases and natural products. Furthermore, we classified natural products according to their mechanism for treating chronic respiratory diseases and describe the ways in which these products can alleviate the pathological symptoms. Simultaneously, we elaborate on the signal transduction pathways and biological impacts of natural products' targeting. Additionally, we present future prospects for natural products, considering their combination treatment approaches and administration methods. The significance of this review extends to both the research on preventing and treating chronic respiratory diseases, as well as the advancement of novel drug development in this field.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"57-88"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139731255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isoliquiritigenin Suppresses Breast Tumor Development by Enhancing Host Antitumor Immunity. Isoliquiritigenin 通过增强宿主抗肿瘤免疫力抑制乳腺肿瘤发展
Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1142/S0192415X2450071X
Chun-Lu Yuan, Xiao-Lu Yang, Lei Sun, Yi-Xin Jiang, Dan-Dan Zhang, Shuang Huang

Isoliquiritigen (ISL), a constituent of licorice, has been shown to possess antitumorigenic effects in diverse cancer types. In this study, we observed that ISL suppressed breast tumor development significantly more effectively in immunocompetent mice than in immunocompromised ones. In exploring the cause of such a discrepancy, we detected robust tumor infiltration of CD8[Formula: see text] T lymphocytes in mice treated with ISL, not seen in tumors derived from vehicle-treated mice. Moreover, we found a dramatic reduction in PD-L1 in both experimental breast tumors and cultured breast cancer cells upon ISL treatment. In further experiments, we showed that ISL selectively elevated miR-200c in breast cancer and confirmed that PD-L1 mRNA is the target of miR-200c in both murine and human breast cancer cells. ISL suppression of PD-L1 was functionally linked to miR-200c/ZEB1/2 because (1) ISL diminished ZEB1/2; (2) knockdown of ZEB1/2 led to the disappearance of PD-L1; and (3) miR-200c antagomiR disabled ISL to reduce PD-L1. We found evidence that ISL reduced the level of PD-L1 by simultaneously intercepting the ERK and Src signaling pathways. In agreement with clinical finding that PD-L1 antibodies enhance efficacy of taxane-based therapy, we showed that ISL improved the tumoricidal effects of paclitaxel in an orthopedic murine breast tumor model. This study demonstrates that ISL-led tumor suppression acts through the augmentation of host antitumor immunity.

甘草的一种成分 Isoliquiritigen(ISL)已被证明对多种癌症具有抗肿瘤作用。在这项研究中,我们观察到 ISL 对免疫功能正常小鼠乳腺肿瘤发生的抑制作用明显强于免疫功能低下的小鼠。在探索造成这种差异的原因时,我们在接受 ISL 治疗的小鼠体内检测到了强大的 CD8[公式:见正文] T 淋巴细胞的肿瘤浸润,而在接受药物治疗的小鼠肿瘤中却看不到这种现象。此外,我们还发现 ISL 治疗后,实验性乳腺肿瘤和培养的乳腺癌细胞中的 PD-L1 均显著减少。在进一步的实验中,我们发现 ISL 能选择性地升高乳腺癌中的 miR-200c,并证实 PD-L1 mRNA 在小鼠和人类乳腺癌细胞中都是 miR-200c 的靶标。ISL对PD-L1的抑制与miR-200c/ZEB1/2的功能有关,因为(1)ISL减少了ZEB1/2;(2)敲除ZEB1/2导致PD-L1消失;以及(3)miR-200c antagomiR削弱了ISL减少PD-L1的作用。我们发现有证据表明,ISL通过同时拦截ERK和Src信号通路来降低PD-L1的水平。与临床发现的 PD-L1 抗体可提高以紫杉类药物为基础的疗法的疗效相一致,我们发现 ISL 在骨科鼠乳腺肿瘤模型中提高了紫杉醇的杀瘤效果。这项研究表明,ISL通过增强宿主的抗肿瘤免疫力来抑制肿瘤。
{"title":"Isoliquiritigenin Suppresses Breast Tumor Development by Enhancing Host Antitumor Immunity.","authors":"Chun-Lu Yuan, Xiao-Lu Yang, Lei Sun, Yi-Xin Jiang, Dan-Dan Zhang, Shuang Huang","doi":"10.1142/S0192415X2450071X","DOIUrl":"10.1142/S0192415X2450071X","url":null,"abstract":"<p><p>Isoliquiritigen (ISL), a constituent of licorice, has been shown to possess antitumorigenic effects in diverse cancer types. In this study, we observed that ISL suppressed breast tumor development significantly more effectively in immunocompetent mice than in immunocompromised ones. In exploring the cause of such a discrepancy, we detected robust tumor infiltration of CD8[Formula: see text] T lymphocytes in mice treated with ISL, not seen in tumors derived from vehicle-treated mice. Moreover, we found a dramatic reduction in PD-L1 in both experimental breast tumors and cultured breast cancer cells upon ISL treatment. In further experiments, we showed that ISL selectively elevated miR-200c in breast cancer and confirmed that PD-L1 mRNA is the target of miR-200c in both murine and human breast cancer cells. ISL suppression of PD-L1 was functionally linked to miR-200c/ZEB1/2 because (1) ISL diminished ZEB1/2; (2) knockdown of ZEB1/2 led to the disappearance of PD-L1; and (3) miR-200c antagomiR disabled ISL to reduce PD-L1. We found evidence that ISL reduced the level of PD-L1 by simultaneously intercepting the ERK and Src signaling pathways. In agreement with clinical finding that PD-L1 antibodies enhance efficacy of taxane-based therapy, we showed that ISL improved the tumoricidal effects of paclitaxel in an orthopedic murine breast tumor model. This study demonstrates that ISL-led tumor suppression acts through the augmentation of host antitumor immunity.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1819-1841"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging the Gap: A Comprehensive Study on Traditional Chinese Medicine Strategies for Managing Adult Irritable Bowel Syndrome. 弥合差距:治疗成人肠易激综合征的传统中医策略综合研究》。
Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1142/S0192415X24500629
Dong-Jue Wei, Hui-Juan Li, Ai-Ping Lyu, Zhao-Xiang Bian, Kewin T H Siah, Linda L D Zhong

Recent studies have witnessed the incorporation of herbal medicine into the management of Disorders of Gut-Brain Interactions (DGBIs), reflecting a paradigm shift toward holistic healing modalities. However, there still exists a substantial gap in comprehending the utilization of Traditional Chinese Medicine (TCM) for Irritable Bowel Syndrome (IBS), particularly beyond the confines of China. This study endeavors to bridge this knowledge gap by meticulously identifying existing guidelines, critically reviewing TCM practices, and crafting contemporary treatment recommendations. We systematically searched several databases to retrieve related evidence in June 2023. Firstly, we employed the AGREE II tool to evaluate the recommended for use of TCM in the treatment of IBS, establishing a structured treatment selection hierarchy for different TCM patterns of IBS patients. Subsequently, we conducted an expert questionnaire to gain insights into the common treatment methods and medication choices practiced by clinical TCM doctors. Based on CM theory and experts' opinions, IBS with predominant Diarrheal (IBS-D) is divided into five Chinese medicine syndrome patterns, and IBS with predominant Constipation (IBS-C) is classified to four. A total of 22[Formula: see text]CM prescriptions were recommended for the management of IBS, 13 for IBS-D and 9 for IBS-C. The findings provide IBS patients with enhanced treatment choices while offering clinical physicians more specific treatment regimens. This research is the first to conduct a comprehensive study that combines guidelines with real clinical practices in the realm of TCM IBS treatment. This serves as a foundation for providing more personalized treatment options and improving the quality of life for patients.

最近的研究表明,中药已被纳入肠脑互动障碍(DGBIs)的治疗中,这反映了整体治疗模式的转变。然而,在理解利用传统中医药治疗肠易激综合征(IBS)方面仍存在很大差距,尤其是在中国以外的地区。本研究通过细致地识别现有指南、批判性地回顾中医实践以及制定当代治疗建议,努力弥补这一知识空白。我们在 2023 年 6 月系统地检索了多个数据库,以获取相关证据。首先,我们采用AGREE II工具对推荐使用中医药治疗肠易激综合征进行评估,针对肠易激综合征患者的不同中医模式建立了结构化的治疗选择层次。随后,我们进行了专家问卷调查,以了解临床中医师常用的治疗方法和药物选择。根据中医理论和专家意见,将以腹泻为主的 IBS(IBS-D)分为五种中医证型,以便秘为主的 IBS(IBS-C)分为四种。共推荐了 22 个[方剂:见正文]中医方剂用于治疗 IBS,其中 13 个用于 IBS-D,9 个用于 IBS-C。研究结果为肠易激综合征患者提供了更多的治疗选择,同时也为临床医生提供了更具针对性的治疗方案。这项研究是首次在中医治疗肠易激综合征领域将指南与实际临床实践相结合的综合性研究。这为提供更个性化的治疗方案和提高患者的生活质量奠定了基础。
{"title":"Bridging the Gap: A Comprehensive Study on Traditional Chinese Medicine Strategies for Managing Adult Irritable Bowel Syndrome.","authors":"Dong-Jue Wei, Hui-Juan Li, Ai-Ping Lyu, Zhao-Xiang Bian, Kewin T H Siah, Linda L D Zhong","doi":"10.1142/S0192415X24500629","DOIUrl":"10.1142/S0192415X24500629","url":null,"abstract":"<p><p>Recent studies have witnessed the incorporation of herbal medicine into the management of Disorders of Gut-Brain Interactions (DGBIs), reflecting a paradigm shift toward holistic healing modalities. However, there still exists a substantial gap in comprehending the utilization of Traditional Chinese Medicine (TCM) for Irritable Bowel Syndrome (IBS), particularly beyond the confines of China. This study endeavors to bridge this knowledge gap by meticulously identifying existing guidelines, critically reviewing TCM practices, and crafting contemporary treatment recommendations. We systematically searched several databases to retrieve related evidence in June 2023. Firstly, we employed the AGREE II tool to evaluate the recommended for use of TCM in the treatment of IBS, establishing a structured treatment selection hierarchy for different TCM patterns of IBS patients. Subsequently, we conducted an expert questionnaire to gain insights into the common treatment methods and medication choices practiced by clinical TCM doctors. Based on CM theory and experts' opinions, IBS with predominant Diarrheal (IBS-D) is divided into five Chinese medicine syndrome patterns, and IBS with predominant Constipation (IBS-C) is classified to four. A total of 22[Formula: see text]CM prescriptions were recommended for the management of IBS, 13 for IBS-D and 9 for IBS-C. The findings provide IBS patients with enhanced treatment choices while offering clinical physicians more specific treatment regimens. This research is the first to conduct a comprehensive study that combines guidelines with real clinical practices in the realm of TCM IBS treatment. This serves as a foundation for providing more personalized treatment options and improving the quality of life for patients.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1589-1611"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The American journal of Chinese medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1